Trials / Completed
CompletedNCT01548404
Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis
A Randomized, Double-Blind, Placebo-Controlled, Repeat-Dose Study of the Efficacy, Safety, Tolerability, and Pharmacodynamics of Subcutaneously-Administered REGN668 in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 109 (actual)
- Sponsor
- Regeneron Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective was to assess the clinical efficacy of repeated subcutaneous (SC) doses of Dupilumab in adult participants with moderate-to-severe atopic dermatitis (AD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Subcutaneous injection altered between back of arms, abdomen and upper thighs. |
| DRUG | Dupilumab | Subcutaneous injection altered between back of arms, abdomen and upper thighs. |
Timeline
- Start date
- 2012-04-01
- Primary completion
- 2013-03-01
- Completion
- 2013-06-01
- First posted
- 2012-03-08
- Last updated
- 2018-08-10
- Results posted
- 2018-08-10
Locations
21 sites across 5 countries: Czechia, France, Germany, Hungary, Poland
Source: ClinicalTrials.gov record NCT01548404. Inclusion in this directory is not an endorsement.